Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound according to the general Formula (I)



(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein :

n is an integer, equal to 1 ~~0, 1 or 2~~ ;

m is an integer, equal to 1 ~~or 2, provided that if m is 2, then n is 1~~ ;

p is an integer equal to 1 or 2;

q is an integer equal to 0 ~~or 1~~ ;

Q is O ~~or NR^3~~ ;

X is a covalent bond ~~or a bivalent radical of formula -O- , -S- or -NR^3-~~ ;

each R^3 independently from each other, is hydrogen or alkyl ;

each R^1 independently from each other, is selected from the group of Ar^1, Ar^1-alkyl and di(Ar^1)-alkyl ;

R^2 is Ar^2~~, Ar^2-alkyl, di(Ar^2)alkyl, Het^1 or Het^1-alkyl~~ ;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, -SO_2- >C=CH-R or >C=N-R, wherein R is H , CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more , phenyl, halo, cyano, hydroxy, formyl and amino radicals;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di(Ar^3)amino, mono-and di(Ar^3alkyl)amino, mono-and di(Het^2)amino, mono-and di(Het^2alkyl)amino, alkylsulfanyl, adamantyl, Ar^3, Ar^3-oxy, Ar^3carbonyl, Het^2, Het-oxy and Het^2carbonyl;

Ar^1 is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy ;

Ar^2 is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl ;

Ar^3 is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, Ar^1carbonyloxyalkyl, Ar^1alkyloxycarbonyl, Ar^1alkyloxyalkyl, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano ;

~~Het^1 is a monocyclic heterocyclic radical selected from the the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, indanyl and chromenyl; each~~

~~heterocyclic radical may optionally be substituted on any atom by one or more radicals elected from the group of halo, oxo and alkyl;~~

Het^2 is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl ;
or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl or benzothienyl ;
or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7a-triaza-cyclopenta[f]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of Ar^1, Ar^1alkyl, Ar^1alkyloxyalkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkylcarbonyl, Ar^1carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxycarbonyl ; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino.

2. (Currently amended) A compound according to claim 1 wherein :

~~n is an integer, equal to 1;~~

~~m is an integer, equal to 1;~~

~~p is an integer equal to 1 or 2;~~

~~q is an integer equal to 0;~~

~~Q is O~~

~~X is a covalent bond;~~

R^1 is Ar^1-alkyl;

R^2 is Ar^2~~, Ar^2-alkyl, di(Ar^2)alkyl or Het^1~~;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, $-SO_2-$, >C=CH-R or >C=N-R, wherein R is CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl, halo and hydroxy radicals;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di(Ar^3)amino, mono-and di(Ar^3alkyl)amino, mono-and di(Het^2alkyl)amino, alkylsulfanyl, adamantyl, Ar^3, Het^2 and Het^2carbonyl;

Ar^1 is phenyl, optionally substituted with 1 or 2 halo radicals ;Ar^2 is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl and alkyloxy;

Ar^3 is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, Ar^1alkyloxycarbonyl, Ar^1alkyloxyalkyl, alkyl, halo and cyano;

~~Het^1 is pyridinyl or a bicyclic heterocyclic radical selected from the group of quinoxalinyl, indolyl, benzothienyl, indanyl and chromenyl; each heterocyclic radical may optionally be substituted on any atom by one or more radicals selected from the group of oxo and alkyl ;~~

Het^2 is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuranyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-

benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, quinoxalinyl, indolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzisoxazolyl, benzothiazolyl,benzofuranyl and benzothienyl ;
or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7a-triaza-cyclopenta[f]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of Ar^1, Ar^1alkyloxyalkyl, halo, alkyl, oxo, alkyloxy, alkylcarbonyl, Ar^1carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxycarbonyl ; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo and hydroxy.

3. (Previously presented) A compound according to claim 1, wherein R^1 is Ar^1methyl and attached to the 2-position or R^1 is Ar^1 and attached to the 3-position .

4. (Previously presented) A compound according to claim 1, wherein R^2-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Cancelled)

6. (Previously presented) A compound according to claim 1, wherein Y is -C(=O)-.

7. (Previously presented) A compound according to claim 1, wherein Alk is a covalent bond.

8. (Previously presented) A compound according to claim 1, wherein L is Het^2.

9. (Currently amended) A compound according to claim 1, selected from the group consisting of:

~~compounds with compound number 219, 270, 269, 281, 408, 393, 72, 164, 253, 258, 267, 286, 317, 318, 313, 308, 331, 366, 31, 32, 4, 71, 218, 259, 287, 285, 306 and 321, as described in Tables 1-6.~~

[2R-trans]-{2-benzyl-4-[4-(1-pyrazin-2-yl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-[2α,4β(S)]]-1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one



[2R-[2α,4β(S*)]-{2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-trans]-enantiomer of {2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone

2R-trans-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-[2α,4β(R(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone

[2R-[2α,4β(S(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone

[2R-trans, R*]-(2-benzyl-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-[2α,4β(R)]]-(2-benzyl-4-{4-[1-(5-methyl-thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-trans]-(2-benzyl-4-{4-[1-(3-hydroxymethyl-thiophene-2-sulfonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone



[2R-[2α,4β(S)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(4-hydroxy-butyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[(2R-trans),(S)]-1-(3-{4-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-(3,4-dichloro-benzyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one



trans-(3,5-bis-trifluoromethyl-phenyl)-[4-{4-[1-(2-chloro-benzoyl)-pyrrolidin-3-yl]-piperazin-1-yl}-2-(3,4-dichloro-benzyl)-piperidin-1-yl]-methanone



[(2R-trans),(S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[(2R-trans),(R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[(2R-trans),(R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[(2R-trans),(S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone

[(2R-trans),(S),(R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[(2R-trans),(R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[2R-[2α,4β(R*)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(1-methyl-1H-pyrrole-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[2R-[2α,4β(R*(S*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[2R-[2α,4β(S*(S*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone

[2R-[2α,4β(S*(R*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone

[2R-[2α,4β(R*(R*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone

[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



cis-(3,5-Bis-trifluoromethyl-phenyl)-(3-phenyl-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone



10. (Cancelled)

11. (Cancelled)

12. (Currently amended) ~~The use of a compound according to claim 1~~A method for treating tachykinin mediated conditions in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound

according to claim 1.

13. (Currently amended) A method ~~The use of a compound according to claim 1-11 for the manufacture of a medicament~~ for treating schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders such as urinary incontinence and nociception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.

14. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

15. (Previously presented) A process for preparing a pharmaceutical composition as claimed in claim 14, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed claim 1.

16. (Original) A process for the preparation of a compound of Formula (I") in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.



(II) (III) (I")

17. (Withdrawn) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I") is reductively hydrogenated, wherein the radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.



(I") (I')

18. (Withdrawn) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of

1) obtaining a compound of Formula (I") according to claim 16;

2) obtaining a compound of Formula (I') according to claim 17.